Life sciences companies challenged by need to minimize health risks without sacrificing data quality during pandemic.
A discussion of how the coronavirus pandemic will have a multitude of impacts on the conduct of trials, as well as on the industry itself.
Looking to the past reminds industry of great strides taken in clinical research for patients.
The rapid evolvement of precision oncology requires real-world data generated at a scale that unlocks insights that can not be provided from clinical trial evidence. Machine learning and large language models can be used to quickly identify information, supporting custom integrated real-world evidence solutions to make informed decisions.
Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.
Best practices for assessing publications.
A look at the prevalence of placebo response in clinical trials and how advanced solutions can mitigate the risk it poses to drug development.
Research can reveal vital information about treatments in the long run.
2020 Tufts CSDD study examines relationship between investigative site personnel diversity and study participant diversity.
Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.
Study evaluates the use of AI-supported medical coding module.
Advancing risk-based auditing one step further by identifying the underlying process deficiencies to enable improved corrective and preventive actions.
Fully-integrated, component-based CDMS offers flexibility, customization, and efficiency.
There's no one-size-fits-all approach during the COVID-19 pandemic
Lessons from six months of conducting clinical trials during the COVID-19 pandemic
Recent study results highlight need for new metrics in ECOG scoring to mitigate variability.
Regulations that apply across geographic borders can provide researchers and patients a firmer foundation on data protection.
COVID-19 forces life sciences industry to make long overdue changes.
Wearable sensors and remote monitoring technology can help HCPs monitor and manage COPD more effectively.
Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.
Concept of flexibility acting as driving force behind industry’s swift response to COVID-19.
Optimizing feasibility through increased data collection.
Trials that address multiple questions simultaneously using a master protocol can be operationally complicated. These complexities can be managed, even in studies used to support a marketing application.
Key takeaways from a survey of 250 oncology patients measuring COVID-19’s impact on patient willingness to participate in clinical trials.
Distinguishing CAR-T and CPI approaches and the clinical trial challenges and complexities associated with each.
2020 Tufts CSDD study examines relationship between investigative site personnel diversity and study participant diversity.
Alleviating sponsor and investigator concerns around sharing of remote-assessment data in accordance with GCP and GDPR standards.